Skip to main content
IDEAYA Biosciences, Inc. logo

IDEAYA Biosciences, Inc. — Investor Relations & Filings

Ticker · IDYA ISIN · US45166A1025 LEI · 549300ULW08F62IJML11 US Manufacturing
Open in API
Filings indexed 466 across all filing types
Latest filing 2026-06-03 Regulatory Filings
Country US United States of America
Listing US IDYA

About IDEAYA Biosciences, Inc.

https://www.ideayabio.com/

IDEAYA Biosciences, Inc. is a clinical-stage precision medicine oncology company focused on the discovery, development, and commercialization of targeted therapeutics for cancer. The company's primary scientific approach is synthetic lethality, an emerging class of precision medicine that targets cancer cells based on specific genetic alterations. IDEAYA develops potential first-in-class and best-in-class therapies for patient populations selected using molecular diagnostics. Its integrated platform combines capabilities in target and biomarker discovery with the development of small molecule and protein degrader therapeutics to address unmet needs in cancer treatment.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 85% confidence The document is a Form 8-K “Current Report” filed with the SEC under the Exchange Act. It discloses an “Other Events” item (Item 8.01) announcing a clinical collaboration. It is not an earnings release, financial report, or specific corporate action like a merger or dividend. Therefore, it falls under general regulatory filings (RNS) as a miscellaneous SEC filing.
2026-06-03 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, containing Regulation FD disclosure and other event updates. Form 8-K filings are standard regulatory filings disclosing material corporate events and are not the actual investor presentation or standalone financial report. This fits the definition of a general regulatory announcement (RNS).
2026-06-01 English
S-3ASR - IDEAYA Biosciences, Inc. (0001676725) (Filer)
Regulatory Filings Classification · 78% confidence The document is a Form S-3 registration statement/prospectus filed with the U.S. SEC under the Securities Act of 1933, outlining a shelf registration for potential future offerings of common stock, preferred stock, debt securities, warrants, and units. It is not an earnings release, annual report, management discussion, dividend notice, or M&A filing; it is a regulatory filing related to securities registration. Therefore, it falls under the catch-all “Regulatory Filings” category (RNS).
2026-05-05 English
8-K - IDEAYA Biosciences, Inc. (0001676725) (Filer)
Earnings Release Classification · 90% confidence The document is a Form 8-K current report under Item 2.02 “Results of Operations and Financial Condition,” disclosing the company’s first quarter financial results via a press release (Exhibit 99.1). This corresponds to an earnings release rather than an annual or interim report, management discussion, or other filing type. Q1 2026
2026-05-05 English
8-K - IDEAYA Biosciences, Inc. (0001676725) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce significant events or updates by a company. The content focuses on a clinical update regarding a Phase 2/3 trial's topline results and plans for an NDA submission. It does not contain comprehensive financial statements or detailed financial analysis. The document is not an earnings release, annual report, or interim report. It is an announcement of clinical trial results and future regulatory plans, typical of a current report (8-K) filing. Given the nature of the content and the form type, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-04-13 English
8-K - IDEAYA Biosciences, Inc. (0001676725) (Filer)
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes a clinical collaboration agreement between IDEAYA Biosciences and AstraZeneca, detailing the nature of the agreement and forward-looking statements. There are no financial statements, detailed financial analysis, or comprehensive report content typical of annual or quarterly reports. The document is not a presentation, earnings release, or management discussion. It is a regulatory filing announcing a material event. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length is 5873 characters, which is sufficient for a full 8-K but does not contain a full report itself, just the announcement of the event.
2026-04-09 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.